{"id":16519,"date":"2021-06-28T14:25:18","date_gmt":"2021-06-28T14:25:18","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=75720"},"modified":"2021-06-28T14:25:18","modified_gmt":"2021-06-28T14:25:18","slug":"junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014","status":"publish","type":"post","link":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/","title":{"rendered":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014"},"content":{"rendered":"

SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014.<\/p>\n

In June 2019, Junshi Biosciences and Anwita Biosciences entered into a license agreement to develop and commercialize JS014 in the Greater China territories (including mainland China, Hong Kong, Macao, and Taiwan).<\/p>\n

About JS014<\/strong>
\nJS014 is a novel recombinant IL-21 and anti human serum albumin (HAS) single domain nanobody fusion protein with a prolonged half-life. It is able to bind specifically to human IL-21R with high affinity and activate T-lymphocyte. The prolongation of half-life can expand the distribution of the drug and enhance the activity of tumor infiltrating lymphocytes in the tumor microenvironment, thereby improving the ability of the immune system to kill tumor cells.<\/p>\n

Preclinical studies demonstrate that JS014 and JS001 (toripalimab) have strong synergistic antitumor effect.<\/p>\n

About Junshi Biosciences<\/strong>
\nFounded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) from the US FDA in February 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at a high risk of progressing to severe COVID-19 and\/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit:\u00a0http:\/\/junshipharma.com<\/a>.<\/p>\n

Contact Information<\/strong><\/p>\n

IR Team:<\/strong>
\nJunshi Biosciences<\/strong>
\ninfo@junshipharma.com<\/a>
\n+ 86 021-2250 0300<\/p>\n

Solebury Trout<\/strong>
\nBob Ai
\nbai@soleburytrout.com<\/a>
\n+ 1 646-389-6658<\/p>\n

PR Team:<\/strong>
\nJunshi Biosciences<\/strong>
\nZhi Li
\nzhi_li@junshipharma.com<\/a>
\n+ 86 021-6105 8800<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) \u2014 Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014. In June 2019, Junshi Biosciences and Anwita [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"\nJunshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) \u2014 Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014. In June 2019, Junshi Biosciences and Anwita [\u2026]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\" \/>\n<meta property=\"og:site_name\" content=\"Myanmar Newswire\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-28T14:25:18+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/myanmarnewswire.com\/#\/schema\/person\/f449613780cb879df549f28a5d10715b\"},\"headline\":\"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014\",\"datePublished\":\"2021-06-28T14:25:18+00:00\",\"dateModified\":\"2021-06-28T14:25:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\"},\"wordCount\":437,\"publisher\":{\"@id\":\"https:\/\/myanmarnewswire.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\",\"url\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\",\"name\":\"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire\",\"isPartOf\":{\"@id\":\"https:\/\/myanmarnewswire.com\/#website\"},\"datePublished\":\"2021-06-28T14:25:18+00:00\",\"dateModified\":\"2021-06-28T14:25:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/myanmarnewswire.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Press Releases\",\"item\":\"https:\/\/myanmarnewswire.com\/category\/press-releases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/myanmarnewswire.com\/#website\",\"url\":\"https:\/\/myanmarnewswire.com\/\",\"name\":\"Myanmar Newswire\",\"description\":\"Latest News, Right Away!\",\"publisher\":{\"@id\":\"https:\/\/myanmarnewswire.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/myanmarnewswire.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/myanmarnewswire.com\/#organization\",\"name\":\"Myanmar Newswire\",\"url\":\"https:\/\/myanmarnewswire.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewswire.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/myanmarnewswire.com\/wp-content\/uploads\/2017\/08\/logo-2.png\",\"contentUrl\":\"https:\/\/myanmarnewswire.com\/wp-content\/uploads\/2017\/08\/logo-2.png\",\"width\":400,\"height\":54,\"caption\":\"Myanmar Newswire\"},\"image\":{\"@id\":\"https:\/\/myanmarnewswire.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/myanmarnewswire.com\/#\/schema\/person\/f449613780cb879df549f28a5d10715b\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/myanmarnewswire.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/myanmarnewswire.com\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire","og_description":"SHANGHAI, China, June 28, 2021 (GLOBE NEWSWIRE) \u2014 Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) has accepted its Investigational New Drug (IND) application for JS014. In June 2019, Junshi Biosciences and Anwita [\u2026]","og_url":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/","og_site_name":"Myanmar Newswire","article_published_time":"2021-06-28T14:25:18+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/#article","isPartOf":{"@id":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/"},"author":{"name":"admin","@id":"https:\/\/myanmarnewswire.com\/#\/schema\/person\/f449613780cb879df549f28a5d10715b"},"headline":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014","datePublished":"2021-06-28T14:25:18+00:00","dateModified":"2021-06-28T14:25:18+00:00","mainEntityOfPage":{"@id":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/"},"wordCount":437,"publisher":{"@id":"https:\/\/myanmarnewswire.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/","url":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/","name":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 - Myanmar Newswire","isPartOf":{"@id":"https:\/\/myanmarnewswire.com\/#website"},"datePublished":"2021-06-28T14:25:18+00:00","dateModified":"2021-06-28T14:25:18+00:00","breadcrumb":{"@id":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/myanmarnewswire.com\/junshi-biosciences-announces-nmpa-acceptance-of-investigational-new-drug-application-for-js014\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/myanmarnewswire.com\/"},{"@type":"ListItem","position":2,"name":"Press Releases","item":"https:\/\/myanmarnewswire.com\/category\/press-releases\/"},{"@type":"ListItem","position":3,"name":"Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014"}]},{"@type":"WebSite","@id":"https:\/\/myanmarnewswire.com\/#website","url":"https:\/\/myanmarnewswire.com\/","name":"Myanmar Newswire","description":"Latest News, Right Away!","publisher":{"@id":"https:\/\/myanmarnewswire.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/myanmarnewswire.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/myanmarnewswire.com\/#organization","name":"Myanmar Newswire","url":"https:\/\/myanmarnewswire.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewswire.com\/#\/schema\/logo\/image\/","url":"https:\/\/myanmarnewswire.com\/wp-content\/uploads\/2017\/08\/logo-2.png","contentUrl":"https:\/\/myanmarnewswire.com\/wp-content\/uploads\/2017\/08\/logo-2.png","width":400,"height":54,"caption":"Myanmar Newswire"},"image":{"@id":"https:\/\/myanmarnewswire.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/myanmarnewswire.com\/#\/schema\/person\/f449613780cb879df549f28a5d10715b","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/myanmarnewswire.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff4aa10d4f36ab9dc3cce9e101792273?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/myanmarnewswire.com\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/posts\/16519"}],"collection":[{"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/comments?post=16519"}],"version-history":[{"count":0,"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/posts\/16519\/revisions"}],"wp:attachment":[{"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/media?parent=16519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/categories?post=16519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myanmarnewswire.com\/wp-json\/wp\/v2\/tags?post=16519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}